Project Grant R01DK146795
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $765,701 Project Grant award dated September 9, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds basic biomedical research to map mechanosensory neural circuits controlling bladder sensation and urination through the completion date of May 31, 2030. The research will employ...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $834,911 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded April 1, 2026, with completion by January 31, 2031. The project focuses on creating a comprehensive roadmap of selective brain-to-gut neural communication circuits, specifically investigating how...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $737,034 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025 through June 30, 2030. The research initiative aims to elucidate regulatory mechanisms governing coenzyme A (CoA) biosynthesis in response to metabolic signals, particularly...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $659,358 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 4, 2025, with completion scheduled for June 30, 2030. The award funds basic biomedical research to elucidate the mechanisms underlying APOL1 nephropathy, a genetic kidney disease disproportionately...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Medical College of Wisconsin, Inc. a Project Grant of $432,625 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop animal models and resources for preclinical lower urinary tract research. The award, effective August 6, 2025, through July 31, 2027, supports the creation of a comprehensive dataset measuring urological...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $191,234 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective August 1, 2025 through July 31, 2030. The research initiative addresses gastric dopaminergic signaling and mucosal injury in Parkinson's disease, investigating mechanisms by which L-amino acid...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $807,282 Project Grant award effective May 11, 2026, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, with completion targeted for February 28, 2031, funds biomedical research to elucidate estrogen-dependent mechanisms underlying diabetic bladder dysfunction (DBD),...
- Federal Grant Award Summary Yale University received a $193,874 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded April 1, 2026, with completion targeted for December 31, 2030. The grant supports research to improve treatment outcomes for urinary incontinence (UI) among women with obesity and Type 2 Diabetes Mellitus (T2DM) through development and...
- Federal Grant Award Summary The University of Vermont received a $320,778 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, through August 31, 2028. This award funds basic biomedical research investigating the intersection of pituitary adenylate cyclase activating peptide (PACAP)/PAC1 receptor signaling and...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $350,902 Project Grant to the University of California, Irvine on July 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This award supports a surgeon-scientist's research and career development training plan focused on investigating urethral dysfunction and female urinary incontinence (UI), a condition affecting millions...
Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $739,141 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on April 22, 2026, with a completion date of March 31, 2031. The research investigates the role of adiponectin signaling in regulating bladder function and lower urinary tract symptoms (LUTS), with particular focus on the molecular mechanisms linking obesity and metabolic syndrome to LUTS. The project will deliver original biomedical research findings through two primary research aims: determining the distinct roles of adipocyte-secreted and smooth muscle-autocrine adiponectin in bladder function through creation of adipose-specific and smooth muscle-specific adiponectin knockout models, and characterizing how dysregulation of adiponectin signaling constitutes a pathway leading to LUTS in obesity and metabolic syndrome conditions. The deliverables from this NIDDK-funded research initiative will include peer-reviewed scientific publications, experimental data on bladder smooth muscle contractile function and cell phenotype regulation, and characterization of plasma adiponectin levels and molecular pathway changes relevant to urologic disease mechanisms. These research outputs are expected to advance scientific understanding of obesity-related urologic dysfunction and potentially identify novel therapeutic targets for treating lower urinary tract symptoms in patients with metabolic disorders.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $739.1k | 4/24/26 |